Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org.
Glucose-lowering therapy after myocardial infarction: more questions than answers
Universität zu Lübeck, Medizinische Klinik II, Ratzeburger Allee 160, D-23538 Lübeck, Germany
* Corresponding author. Tel. +49 451 500 2501; Fax +49 451 500 6437. E-mail: heribert.schunkert@innere2.uni-luebeck.de
This editorial refers to ‘The impact of glucose-lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial’
‘Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart’ by M. Alselmino et al.,
by L.G. Mellbin et al., on page 166 and 
on page 177
Footnotes
doi:10.1093/eurheartj/ehm518 
doi:10.1093/eurheartj/ehm519
The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.
| The first 10% of the full text of this article appears below. |
The DIGAMI I study demonstrated in 620 diabetic patients with acute myocardial infarction that insulin–glucose infusion followed by multidose subcutaneous insulin decreases long-term mortality as compared with standard therapy.1 About 10 years later, the DIGAMI II study reported on 1253 diabetic patients with acute myocardial infarction allocated to three treatment arms including acute insulin–glucose infusion followed by insulin-based long-term glucose control (group 1), insulin–glucose infusion followed by standard glucose control (group 2), and routine metabolic management according to local practice (group 3).2 Surprisingly, neither all-cause mortality nor morbidity (stroke and non-fatal reinfarctions) differed between the three groups.2 Mellbin
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial
- Linda G. Mellbin, Klas Malmberg, Anna Norhammar, Hans Wedel, Lars Rydén, and for the DIGAMI 2 Investigators
EHJ 2008 29: 166-176.[Abstract] [FREE Full Text] - Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart
- Matteo Anselmino, John Öhrvik, Klas Malmberg, Eberhard Standl, Lars Rydén, and on behalf of the Euro Heart Survey Investigators
EHJ 2008 29: 177-184.[Abstract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  F. Cosentino, L. Rydén, P. Francia, and L. G. Mellbin CHAPTER 14 Diabetes Mellitus and Metabolic Syndrome ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. Mellbin, K. Malmberg, A. Norhammar, and L. Ryden Glucose, insulin, and coronary heart disease: reply Eur. Heart J., April 2, 2008; 29(8): 1076 - 1077. [Full Text] [PDF]
|
|